COVID-19 Pharmacological Management

COVID-19 Pharmacological Management


  1. CBC with differential cell count

  2. Creatinine, electrolytes, extended lytes

  3. Coagulation studies (including INR, PTT and fibrinogen)

  4. CRP, LDH, ferritin and d-dimers

  5. Liver function tests

  6. Urine pregnancy test in reproductive-age women

  7. Blood cultures x 2

  8. Troponins

Chronic Disease Guidance

AGA clinical practice expert commentary suggest (for COVID-19 confirmed):

  • Hold thiopurine, methotrexate, tofacitinib and biological therapies during the viral illness. May be restarted after complete symptom resolution or, if available, when follow-up viral testing is negative or serologic tests demonstrate convalescent stage of illness

American college of Rheumatology expert advice suggest (for documented or presumptive COVID-19):

  • Hydroxychloroquine or chloroquine may be continued
  • Sulfasalazine, methotrexate, leflunomide, immunosuppressants, non-IL-6 biologics and JAK inhibitors should be held. Precise duration of hold not determined (call rheumatology)
  • Stop NSAIDS in severe respiratory symptoms
  • Do not suddenly stop corticosteroids
  • IL-6 receptor inhibitors may be continued (call rheumatology)

More Information

To provide guidance for physicians in the pharmacological management of COVID-19 patients